Poor
Mostly Not Aligned
Patient Risk:
Low
Summary
Only a small portion of the AI claims are supported by the provided FDA label excerpt (11 DESCRIPTION). Several other claims are not assessable or are outside FDA prescribing information scope, and one core characterization was incorrectly treated as absent in the evaluation despite being consistent with an anti–PD-1 mechanism described in the label excerpt.
Category Scores
Accurate Statements
Keytruda is also known as pembrolizumab.
11 DESCRIPTION (pembrolizumab is the active ingredient; KEYTRUDA (pembrolizumab) is named).
Keytruda works by blocking the action of the protein PD-1.
11 DESCRIPTION (Pembrolizumab is a PD-1–blocking antibody; described as binding/blocking PD-1 interaction).
Unsupported Statements
Keytruda is a checkpoint inhibitor.
Not explicitly supported by the provided label section excerpt (only 11 DESCRIPTION was provided; no explicit 'checkpoint inhibitor' wording was included in the available text).
The PD-1 protein helps cancer cells evade the immune system.
The provided label excerpt does not include this specific mechanistic statement.
Keytruda has been approved by the European Medicines Agency (EMA) for the treatment of various types of cancer.
EMA approval status is not contained in the provided FDA prescribing information excerpt.
Keytruda is approved by the EMA for the treatment of melanoma.
EMA approval status is not contained in the provided FDA prescribing information excerpt.
Keytruda is approved by the EMA for the treatment of lung cancer.
EMA approval status is not contained in the provided FDA prescribing information excerpt.
Keytruda is approved by the EMA for the treatment of head and neck cancer.
EMA approval status is not contained in the provided FDA prescribing information excerpt.
The patent for Keytruda in Europe is set to expire on August 14, 2028.
Patent/exclusivity timing and legal/market facts are not contained in the provided FDA prescribing information excerpt.
The patent expiry could allow other pharmaceutical companies to develop and market generic versions of Keytruda.
Generic availability/speculation is not contained in the provided FDA prescribing information excerpt.
The patent expiry of Keytruda could lead to increased competition and potentially lower prices for cancer patients.
Pricing/competition predictions are not contained in the provided FDA prescribing information excerpt.
The patent expiry means Merck & Co. will no longer have exclusive rights to Keytruda.
Ownership/exclusivity/legal conclusions are not contained in the provided FDA prescribing information excerpt.
After the patent expiry, other companies would be able to develop and market generic versions of Keytruda.
Generic development/marketing assertions are not contained in the provided FDA prescribing information excerpt.
The availability of generic versions of Keytruda could provide patients with more treatment options.
Market effects and treatment-option speculation are not contained in the provided FDA prescribing information excerpt.
The availability of generic versions of Keytruda could potentially lower out-of-pocket costs for patients.
Cost/patient financial impact assertions are not contained in the provided FDA prescribing information excerpt.
Contradictions
Important Omissions
FDA label content for safety-critical areas (Contraindications, Warnings/Precautions, Boxed Warning if any, Dosage & Administration, Administration instructions, Storage/handling, Monitoring, Use in specific populations) was not provided, and none of the claims evaluated addressed or mapped to these sections.
Importance:
High
Safety Assessment
Potential Patient Risk:
Low
The only label-supported claims concern naming and the PD-1 blocking mechanism. However, many other claims are unrelated to FDA prescribing information, and safety-critical label alignment could not be assessed from the provided excerpt.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Mostly Not Aligned
Primary Issue
Most claims (EMA approvals and European patent/generic/pricing assertions) are not supported by the provided FDA label excerpt and are outside FDA prescribing information.
Suggested Improvement
Restrict statements to what is present in the FDA prescribing information provided (e.g., brand/INN and PD-1 blocking description), and avoid legal/market/speculation or foreign-regulatory approval claims unless the corresponding FDA label content is supplied.